EverImmune Raises €5M in Series A Funding

EverImmune, a Villejuif, near Paris, France-based biotechnology company specialized in the development of live biotherapeutic products in the field of microbiota oncology, raised more than €5m (approx. $6M) in Series A funding.

Backers included undisclosed private investors.

Created in 2016 by co-founders Pr. Laurence Zitvogel and Dr. Romain Daillere as a spinoff from Gustave Roussy, a cancer institute, based near Paris, France, EverImmune harnesses the gut microbiota for the development of a theragnostic approach combining diagnostic and therapeutic technologies to restore the response to Immune Checkpoint Inhibitors (ICIs) in cancer patients

The proceeds of this funding will support the clinical development of Oncobax® AK (Akkermansia), a Live Biotherapeutic Product (LBP) used as an oral adjuvant to anticancer immunotherapies. This technology is designed to safely boost the immune system and restore sensitivity to immunotherapies in primary resistance settings. The company intends to start its first Phase I clinical trial for Oncobax AK in Q2, 2022 – in Non-Small Cell Lung Cancer (NSCLC) and Renal Cell Cancer (RCC).

Following the first preclinical results obtained in 2016, EverImmune plans to launch the Oncobax AK clinical trial, initially with 66 patients (33 NSCLC and 33 RCC), followed by a cohort extension of an extra 50, to evaluate its safety and efficacy. Oncobax AK – lyophilized, formulated in delayed release capsules – will be used as an oral adjuvant for cancer immunotherapy.

The company, which is part of ONCOBIOME, a European program dedicated to microbiome and cancer, funded by the European Union, also develops a broader pipeline of products comprising additional bacteria endowed with robust adjuvant potential in different types of cancer, such as breast and colon cancers.

EverImmune has five staff.